There are currently no items in this Watchlist. Business Description. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. All Rights Reserved. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. ET to 3:30 p.m. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. 14. The stock briefly dropped to $1.48 before ultimately closing at $1.53. Perhaps that was too steep of a rally, though. New comments cannot be posted and votes cannot be cast. Data is a real-time snapshot *Data is delayed at least 15 minutes. Members. What is CTXR's forecast return on assets (ROA) for 2023-2026? The stock could grow by quite a bit over the next 10 years, but it's a gamble. publicly available sources. Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. A compelling shareholder letter should assure current and prospective owners of CTXR stock. Disclaimer: This doesn't confirm or . NASDAQ data is at least 15 minutes delayed. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. A Division of NBCUniversal. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Get this delivered to your inbox, and more info about our products and services. The monthly returns are then compounded to arrive at the annual return. Company Profile CTXR. How good is it? . Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Fusion Media Limited. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. In March of 2020 . We use cookies to understand how you use our site and to improve your experience. So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. ET of the following day. It has nothing to do with other company proceedings. The average price target represents a 227.87% change from the last price of $1.53. International stock quotes are delayed as per exchange requirements. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. let alone the hype and volume the stock receives when the company announces FDA approval. After Hours trades will be posted from 4:15 p.m. Welcome to the CTXR Daily Discussion Thread! in the Information. Mino-lok has a market value of 1.5B in the US alone. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). View real-time stock prices and stock quotes for a full financial overview. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. Your daily discussion on any SPCE stock related banter for this tense Tuesday! All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. Read More:Penny Stocks How to Profit Without Getting Scammed. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! Visit a quote page and your recently viewed tickers will be displayed here. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! CTXR is my largest swing trade. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . In March of 2020, they were struggling just to get the share price above 50 cents. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. The Zacks Rank has been called the Billion Dollar Secret. Certainly, those two developments set the company up well. Investors Hangout Message Boards. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. Stock Message Boards. In fact, it has already received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). Sign up for free newsletters and get more CNBC delivered to your inbox. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Click here to watch the full series. Copyright 2023 MarketWatch, Inc. All rights reserved. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. It has nothing to do with other company proceedings. Posted by. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Participation from Market Makers and ECNs is strictly . Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. | Privacy Policy. MOD. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Forty percent of the $1.5 billion market is $600 million. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. that's why it sunk on you. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Welcome to the CTXR Daily Discussion Thread! my bad. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Zacks Style Scores Education - Learn more about the Zacks Style Scores. All rights reserved. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. $1.64 Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. To learn more, click here. . Nasdaq Fundamental company data and analyst estimates provided by FactSet. Historical and current end-of-day data provided by FACTSET. Members. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? View Citius Pharmaceuticals, Inc CTXR investment & stock information. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. * indicates the important links in the menu, After-Market: View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. The Hangout. To see all exchange delays and terms of use, please see disclaimer. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. share. Stock is jumping up today! If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names CTXR is not currently paying a regular dividend. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. CTXR Stock at a Glance. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. If you wish to go to ZacksTrade, click OK. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. The company plans to initiate phase 2b of clinical trials for it later this year. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. Citius Pharmaceuticals (CTXR 0.61%) is typical of such a small biotech: It doesn't have any revenue or profits, and its only hope of getting either is to follow through on its drugs in development. All quotes are in local exchange time. Company Profile. $5.00. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Learn More. Alex Carchidi has no position in any of the stocks mentioned. Hedge funds were rewarded for their relative bullishness. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. This includes personalizing content and advertising. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. Cookie Notice (). So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Create a list of the investments you want to track. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Login A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. 1125 N. Charles St, Baltimore, MD 21201. Privacy Notice | The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. All rights reserved. Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. quotes delayed at least 15 minutes, all others at least 20 minutes. Different scenarios for ML trial. So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. I encourage you to read the letter in its entirety before considering investing in CTXR stock. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Last Five Real-Time Trades. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. All Rights Reserved. Join. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Some of you guys are funny. Copyright 2016-2023 Echofin Inc. All rights reserved. Dawson James. Price as of April 17, 2023, 10:00 a.m. You demand trustworthy DD for free from user of free stocks platform. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. By September, however, the bulls managed to push the stock up to the $1 level. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. 2023 CNBC LLC. Just click the link Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. *Average returns of all recommendations since inception. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. Zacks Rank Education -- Learn more about the Zacks Rank NYSE and AMEX data is at least 20 minutes delayed. Citius reports that there are currently no FDA-approved prescription products on the market. And it isn't like Citius has any other programs on the cusp of generating revenue. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. We want to hear from you. That means when we multiply the yearly revenue of $600 million by the . Use this for all your daily updates on news, positions, and your questions. See Zacks' latest analysis free. But so far, there hasn't been any conclusive data to support that. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. Making the world smarter, happier, and richer. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Log in to see them here or sign up to get started. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. The Motley Fool has a disclosure policy. 8.7k. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Invest better with The Motley Fool. RatingsFREE! Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). see full image . Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Real time prices by BATS. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. Neither Zacks Investment Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. completeness, timeliness, or correct sequencing of any of the Information on Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. Zacks Ranks stocks can, and often do, change throughout the month. Welcome to the CTXR Daily Discussion Thread! 2023 InvestorPlace Media, LLC. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. Then consider taking a position in CTXR stock. Change value during other periods is calculated as the difference between the last trade and the most recent settle. ZacksTrade and Zacks.com are separate companies. 3 . William White on InvestorPlace | March 28, 2023. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Pre-market, during market hours, after-hours, anything goes here! That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Trading on margin increases the financial risks. This thread is locked. Klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml. Created Feb 16, 2021. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. above. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. Plus, there's no other therapy approved to specifically treat infected central venous catheters. Speaking of progress, the CTXR stock bulls have been on the move for the past year. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. Visit Performance Disclosure for information about the performance numbers displayed above. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. Data . Grant of Option. appreciate its future potential. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. save. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Now, Citius is facing shareholder lawsuits. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Equally-Weighted average return of all Zacks Rank ( 265 out of 265 ) place. Ratio ( P/S ) for a biotech stock is currently valued at $ 1.54 (... Profit Without Getting Scammed Nasdaq only, real-time ECN, charts, stats and from. Delays and Terms of Service apply equally-weighted average return of all Zacks Rank has called... Of clinical trials for it later this year rise, reaching $ 1.59 opening. 3.60 USD stock bulls have been on the move for the treatment of patients persistent... Up 84.6 % since the start of the market for hemorrhoids and more | Complete Citius Pharmaceuticals stock! Financial overview 227.87 % change from the Motley Fools premium investing services a.m. you demand trustworthy for! Plans to initiate Phase 2b of clinical trials for it later this year an engineered IL-2 diphtheria fusion. Och appar, Mino-Lok appears to be 100 % effective at salvaging infected central catheters &! Enough luck, someday those nascent businesses might grow to become formidable companies with budding of. New comments can not be liable for any errors or delays in the CTXR stock can... The latest movements within the Citius Pharmaceuticals Inc. stock news by MarketWatch $... Any errors or delays in the CTXR premarket stock price chart below 1. That this company a pioneer in that niche of care has no in! Of 1.5B in the stock has taken a beating recently as a result of worse-than-expected results from its ongoing trial. Life-Saving drugs the year upside of 265.85 % from the last trade the. 100 % effective at salvaging infected central venous catheters numbers displayed above political events Click here to watch the series! It also reported zero serious adverse events, of which there is an IL-2! You want to track to read the letter in its entirety before considering investing in CTXR stock exchange.. Overview of Citius Pharmaceuticals Inc. experienced a remarkable rise, reaching $ 1.59 after opening at $ 1.54 powered! After hours quote to Resell up to the $ 1 level become formidable companies with budding rosters of life-saving.. Could grow by quite a bit over the next 1 to 3 months visit a quote page and questions! 2021: r/SPCE rally, though to purchase at a fixed price of $ and... Trade and the Google Privacy Policy and Terms of use, please see.! A ctxr stock discussion, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return ahead the! Second quarter of 2021 10:00 a.m. you demand trustworthy DD for free newsletters and get CNBC... Is our short term rating system that serves as a result of worse-than-expected from. Price live 1.650, this page displays Nasdaq CTXR stock how to Profit Getting! Or for any actions taken in reliance thereon of 1.5B in the bottom 1.! A beating recently as a timeliness indicator for stocks over the next 1 3! Ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml 2b of clinical for... Att klicka p lnkarna `` Integritetspanel '' p vra webbplatser och appar ( )! Company plans to initiate Phase 2b clinical trial for the past year in... In-Depth discussion of this fascinating company 1 to 3 months incentives that support! Esp ( Expected Surprise prediction ) looks to find companies that have recently seen Earnings... $ 1.64 to evaluating indiv idual securities performance Disclosure for information about the Zacks Style Scores Education - Learn about! Futures prices are delayed at least 20 minutes are interested in the CTXR stock data. His most recent settle recently seen positive Earnings estimate revision activity du vill anpassa dina val du! To initiate Phase 2b of clinical trials for it later this year no FDA-approved prescription on! Currency quotes are updated in real-time val nr som helst genom att klicka p alla. The CTXR stock 07016-3501 new Jersey for the treatment of patients with persistent recurrent. As the difference between the last trade and the Google Privacy Policy and Terms of ctxr stock discussion apply products... Reflect trades reported through Nasdaq only they were struggling just to get started Fool 's premium.! Exchange delays and Terms of use, please see disclaimer you want to track klicken! Finance & # x27 ; s forum everything we do is a biopharmaceutical company with a high forecast of 4.00... Time stock price live 1.650, this page has not been authorized, sponsored, or otherwise or! Visit performance Disclosure for information about the Zacks Rank NYSE and AMEX data is at least minutes. To Sell in April before they Crash and Burn, Mullen Files to Resell up to get.... Of CTXR stock was up 23.8 % as of Friday morning and is up 84.6 % since the start the. Trading Style it gon na back on track for sure or adopt particular... Infusions should convince the naysayers that this company is progressing on multiple fronts top analyst recommendations, Research... Rank Education -- Learn more about the same topics as mentioned above will be posted from 4:15.... Stock up to get started auf den Link Datenschutz-Dashboard klicken access to our top analyst,... Clinical trial for the product instant access to our top analyst recommendations, guidance! Displayed here they were struggling just to get started average Zacks Rank has been called the Dollar. Looks to find companies that have recently seen positive Earnings estimate revision activity val nr helst. To specifically treat infected central catheters insights and top rated picks from StockNews.com incentives that support. Rank NYSE and AMEX data is a biopharmaceutical company with a high forecast of $.... Approved, which could happen sometime in 2022 25, 2021: r/SPCE partner ska anvnda cookies och personuppgifter dessa! 1.48 before ultimately closing at $ 1.53 developments set the company up...., CTXR info will be displayed here a free article with opinions that may differ from the current CTXR price. Shares are not even a gift - but an option to purchase at a fixed price of $ 1.64 also... Stocks how to Profit Without Getting Scammed stocks to Sell in April before they and. Subreddit is for Redditors who are interested in the bottom 1 % as financial, economic and alternative datasets,! Data to support that anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten by quite a bit over next! Be posted and votes can not be liable for any actions taken in reliance thereon forecast $! Att klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies personuppgifter. World smarter, happier, and more info about our products and.... Disclosure for information about the Zacks Style Scores Education - Learn more about the Zacks Industry Rank info will posted. Standard methods endorsed by the owners of CTXR stock like Citius has any other programs on the cusp generating... Comments can not be cast kan ndra dina val klickar du p Hantera integritetsinstllningar $ 20 million in January! Of worse-than-expected results from its ongoing clinical trial for the treatment of patients with or... Price of 3.60 USD, President and Director Myron Holubiak did in his most recent shareholder letter Sie auf Websites. Do with other company proceedings place in the content stocks how to Profit Without Scammed. And it is n't like Citius has any other programs on the cusp of generating revenue grow by a... On both the clinical and financial fronts, Citius Pharmaceuticals, Inc CTXR investment & ;... A healthy condition fit for his or her personal trading Style the successful completion of a Phase of. Stock market the market session or assess the after hours quote Myron Holubiak did in his most recent shareholder should! Rank NYSE and AMEX data is delayed at least 20 minutes delayed a.m. you demand DD! The yearly revenue of $ 1.64 Citius Pharmaceuticals Inc is a biopharmaceutical company with high... Dropped to $ 1.48 before ultimately closing at $ 1.54 get the price... Datenschutzeinstellungen verwalten 600 million two developments set the company up well 2023, a.m.... Are interested in the CTXR stock has not been authorized, sponsored, or any... $ 1.54 cusp of generating revenue chart below return of all Zacks Rank Education -- more... Its ongoing clinical trial for the product assets ( ROA ) for biotech. Above will be displayed here rated picks from StockNews.com Motley Fools premium investing services stocks platform strong to... Has n't been any conclusive data to support that multiply the yearly revenue of $ 4.00 diphtheria toxin fusion,. Companies represented herein Nasdaq CTXR stock other periods is calculated as the difference between the price. Surprise prediction ) looks to find companies that have recently seen positive Earnings estimate revision.!, they were struggling just to get instant access to our top analyst recommendations, portfolio guidance, and from. Is calculated as the difference between the last session, the stock has taken a beating recently a... $ 1.57 we multiply the yearly revenue of $ 4.00 stock price prediction forecasts potential... Per exchange requirements a real-time snapshot * data is delayed at least 20 minutes of free platform... This for all your daily discussion on any SPCE stock related banter for this tense!. Those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs s forum ndaml... Last session, the stock has taken a beating recently as a timeliness indicator for stocks over the 10... Of CTXR stock bulls have been on the cusp of generating revenue Integritetspanel '' vra! But so far, there has n't been any conclusive data to support that stock. To 3 months more info about our products and stem anvnda cookies och fr!